Results 111 to 120 of about 5,124 (246)

Direct oral anticoagulants: first airbag

Медицинский совет, 2019
The safety profile of oral anticoagulants (DOACs) was confirmed in the large-scale studies, the increased risk of hemorrhagic events does still exist, which may be caused by the nature of the patient’s concomitant pathology, the resulting injury or the ...
A. N. Sokolova, A. I. Skripka
doaj   +1 more source

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies [PDF]

, 2017
Stephen H. Norris, Steven Ramael, Ippei Ikushima, Wouter Haazen, Akiko Harada, Viktoria Moschetti, Susumu Imazu, Paul Reilly, Benjamin Lang, Joachim Stangier, Stephan Glund   +10 more
openalex   +1 more source

Jefferson Digital Commons quarterly report: July-September 2018 [PDF]

, 2018
This quarterly report includes: New Collection Alert Articles Code Red: Battling the Plague of Gun Violence Dissertations From the Archives Grand Rounds and Lectures House Staff Quality Improvement and Patient Safety Posters Journals and Newsletters ...
Copeland, LIBT, James, Duinkerken, MSI, Kelsey   +1 more
core   +1 more source

Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran

Vascular Health and Risk Management, 2019
David Giannandrea,1,2,* Anna Mengoni,3,* Erberto Carluccio,3 Giuseppe Ambrosio31Neurology Departement - Stroke Unit, Gubbio/Gualdo Tadino Hospitals, Perugia, Italy; 2Association “Naso Sano”, Umbria Regional Registry of No-Profit Organization,
Giannandrea D, Mengoni A, Carluccio E, Ambrosio G   +3 more
doaj  

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab

Case Reports in Cardiology, 2017
Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation.
Steven Song, Joselle Cook, Clive Goulbourne, Matthew Meade, Louis Salciccioli, Jason Lazar   +5 more
doaj   +1 more source

Modern strategy of antithrombotic therapy in patients with coronary artery disease and atrial fibrillation after percutaneous coronary intervention

Российский кардиологический журнал, 2019
Reducing of cardiovascular risk, morbidity and mortality is considered as one of the main aims of modern cardiology, which should help increase life expectancy.
Yu. A. Karpov
doaj   +1 more source

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. [PDF]

, 2019
BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction.
Arnold, Susan E., Bhatt, Deepak L., Jennings, Lisa K., Lee, John S., Mays, Michael C., Pollack, Charles V., Umstead, Bret R., Weitz, Jeffrey I., Xu, Sherry   +8 more
core   +1 more source

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab

Vascular Health and Risk Management, 2016
Tiffany Y Hu,1 Vaibhav R Vaidya,2 Samuel J Asirvatham2,31Mayo Medical School, 2Division of Cardiovascular Diseases, Department of Internal Medicine, 3Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USAAbstract: Novel oral ...
Hu TY, Vaidya VR, Asirvatham SJ
doaj  

Idarucizumab for dabigatran reversal

Thrombosis research, 2023
Background: Idarucizumab has been approved to reverse the anticoagulant effect of dabigatran. However, there is little knowledge of the effectiveness and safety of idarucizumab in daily practice. Aims: This systematic review and meta-analysis aims to evaluate the use, effectiveness and outcomes of idarucizumab.
van der Horst, S. F. B., Martens, E. S. L., den Exter, P. L., Bos, M. H. A., van Mens, T. E., Huisman, M. V., Klok, F. A.   +6 more
openaire   +1 more source

Idarucizumab dosing in patients with excessive dabigatran body burden [PDF]

, 2018
Luke Yip, Jiaxuan Deng
openalex   +1 more source